OncoMatch/Clinical Trials/NCT07194044
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Is NCT07194044 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for metastatic ewing sarcoma.
Treatment: Vincristine · Doxorubicin · Cyclophosphamide · Ifosfamide · Actinomycin · Irinotecan · Cabozantinib · Topotecan · Temozolomide · Etoposide · Liposomal doxorubicin — This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics as related to adaptation and extinction to populations of cancer cells that similarly adapt and that we are attempting to make extinct, resulting in a cure for the patient. Such principles include an initial intense first strike to deplete the bulk of the cancer cells, followed by a series of sequential second strikes towards eliminating residual, resistant populations, followed by a prolonged period of maintenance chemotherapy to eliminate any remnant cells, using agents generally regarded to be active against newly diagnosed ES.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Biomarker criteria
Required: CIC rearrangement
Disease stage
Required: Stage IV
Excluded: Stage LOCALIZED
Metastatic disease required
widely metastatic Ewing sarcoma or metastatic CIC-rearranged sarcoma
Prior therapy
Cannot have received: systemic therapy
Exception: may have started an initial cycle of vincristine/doxorubicin/cyclophosphamide (VDC) prior to enrollment, but not ifosfamide/etoposide (IE)
must not have received any prior systemic therapy with the exception that they may have started an initial cycle of vincristine/doxorubicin/cyclophosphamide (VDC) prior to enrollment, i.e. VDC may have been given, but not ifosfamide/etoposide (IE)
Cannot have received: myelosuppressive chemotherapy
history of cancer that was treated with myelosuppressive chemotherapy or radiation therapy
Cannot have received: radiation therapy
history of cancer that was treated with myelosuppressive chemotherapy or radiation therapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham (Children's of Alabama) · Birmingham, Alabama
- Phoenix Children's Hospital · Phoenix, Arizona
- Connecticut Children's Medical Center · Hartford, Connecticut
- University of Florida · Gainesville, Florida
- Nemours Jacksonville · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify